Introduction Intradermal injection of botulinum toxin type A (BoNT/A) has been used off-label by many clinicians for face-lifting. Previous studies on abobotulinumtoxinA (ABO) (Dysport®; Ipsen Biopharm Ltd.) have demonstrated clinical efficacy in face-lifting when compared to normal saline solution (NSS). However, few clinical studies have evaluated ABO in terms of duration of sustained effects for face-lifting. Methods Thirty subjects were enrolled, and their face was injected with ABO at a dilution of 1 vial:7 mL (500 U in 7 mL of NSS) using an intradermal injection technique. Standardized photographic documentation was obtained using a two-, and three-dimensional imaging system (Vectra H1, Canfield Scientific, Inc, Fairfield, NJ) at baseline, immediately after injection, 2 weeks after injection and at 1 , 2 , 3 , 4 , 5 and 6 months of follow-up after treatment. The face-lifting effects were graded by both the subjects and two blinded dermatologists who compared photographs taken at the different time points. Side effects were also recorded at the end of the study. Results Of the 30 subjects, 28 completed treatment and attended every follow-up visit. All subjects were female with Fitzpatrick skin type II to IV. The average age of the subjects was 27.6 ± 3.4 (range 22–34) years. The total number of ABO units used varied for each subject (range 200–250 U), with the average (± standard deviation) dose being 237 ± 19 units. Most of the subjects reported significant face-lifting up to 3 months post-procedure. However, face-lifting assessed by blinded dermatologists was notably lower than that of each patient’s evaluation. The difference in the facial contouring volume of the nasolabial fold and jawline, as measured by the Vectra H1 imaging system, was statistically significant from baseline up until 3 months after injection ( p = 0.001 and p = 0.001, respectively). The only side effect found in this study was minimal bruising, which was seen in 13.8% of subjects. None of the subjects reported facial asymmetry, either at rest or during facial expression. Conclusion The results of this study demonstrate the face-lifting effect of ABO intradermal injection. The results show sustained effects up to 3 months after injection.

Background Enlarged facial pores are one of the common skin signs of photoaging that patients seek treatment for. However, objective data and long‐term assessment on the efficacy and safety of therapeutic procedures for this condition are limited. Objective To objectively evaluate the efficacy and safety of a 1064‐nm picosecond laser with microlens array (MLA) for pore tightening. Methods Twenty‐five patients with enlarged pores received three treatments with a 1064‐nm picosecond laser coupled with MLA at 4‐week intervals. Patients were evaluated using objective (measurement of pore volume using three‐dimensional photography) and subjective (clinical evaluation by two blinded dermatologists) assessments at baseline and at the 1‐, 3‐, and 6‐month follow‐ups. Adverse effects were also recorded during each visit. Results After three treatments, there was a significant reduction of pore size from baseline (p < 0.001). The improvement in pore size appearance significantly continued from the 1‐month to the 6‐month follow‐up visits (p = 0.013). The total average pore size was 1.15652 ± 0.614322 and 0.8087 ± 0.50515 at baseline and at 6 months after the final treatment, respectively, resulting in an average of 30% reduction in pore size. No cases of dyspigmentation, textural alteration, or scarring were documented. Conclusion Fractional 1064‐nm picosecond laser appears to be effective and safe for reducing pore size in Asians with minimal transient side effects.

Background The Vitiligo Extent Score (VES) and Self-Assessment Vitiligo Extent Score (SA-VES) have not been formally validated in Thai population. Objective To evaluate reliability, validity and feasibility of the VES and SA-VES in Thai vitiligo patients. Methods Vitiligo lesions from 100 patients were evaluated by 2 independent dermatologists using VES and Vitiligo Area Scoring Index (VASI). Reliability was assessed by comparing VES scores between physicians. Validity was determined by comparison among the VES, VASI, and SA-VES instruments. Patients scored their vitiligo severity using the SA-VES. Results The reliability of the VES was excellent (inter-rater reliability: 0.997, 95% confidence interval: 0.995–0.998). There was very strong correlation between the VES and VASI ( r =0.976, p <0.001), and strong correlation between the VES and SA-VES ( r =0.890, p <0.001), and between the VASI and SA-VES ( r =0.866, p <0.001). Moderate correlation among the VES, VASI, and SA-VES was observed in patients with segmental or <1% body surface area (BSA) vitiligo. Ninety-five percent of patients rated the SA-VES as easy to moderately easy. Conclusion The VES has reliability and validity comparable to that of the VASI. The SA-VES is an user-friendly instrument that correlated well with physicians’ scoring methods in patients with non-segmental or >1% BSA vitiligo.